6:07 PM
 | 
Oct 22, 2012
 |  BC Extra  |  Clinical News

Laquinimod meets Crohn's endpoints

Active Biotech AB (SSE:ACTI) gained SEK2.50 to SEK63.40 on Monday after it and Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) reported data from a Phase IIa trial of oral laquinimod to treat moderate to...

Read the full 149 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >